Rosetta Genomics lifts at-the-market equity offering to $10 million

Deal arranged with Cantor Fitzgerald; proceeds fund corporate purposes

By Devika Patel

Knoxville, Tenn., March 31 - Rosetta Genomics Ltd. increased its at-the-market equity offering with agent Cantor Fitzgerald & Co. to $10 million from $5.9 million, according to a prospectus supplement filed Monday with the Securities and Exchange Commission. The deal was announced March 22.

The ordinary stock is to be sold on a commercially reasonable efforts basis.

Cantor will be paid a 3% commission.

Proceeds will be used for operations and other general corporate purposes, including debt repayment or refinancing, working capital, intellectual property protection and enforcement, capital expenditures, investments, acquisitions or collaborations, research and development and product development.

Based in Rehovot, Israel, Rosetta Genomics develops and provides microRNA-based molecular diagnostics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.